Mandate

Vinge advises FSN Capital in connection with acquisition of Saferoad

August 16, 2018 M&A

Vinge has, in its capacity as Swedish local counsel, advised FSN Capital V (“FSN Capital”) in connection with their buy-out of Saferoad Holding ASA (“Saferoad”), a company that is listed on the Oslo Stock Exchange.

Earlier in May, FSN Capital announced an agreement to launch a recommended voluntary cash offer to acquire the entire issued share capital of Saferoad, a Norwegian based market leading provider of road safety and road infrastructure products and solutions in Europe (#1 or #2 in its core niche markets). FSN Capital has received pre-acceptances from shareholders representing approximately 64% of Saferoad’s issued share capital. The transaction is subject to approval from the competition authorities, as well as other conditions including that more than 90% of the share capital accept the offer.
 
Vinge’s team consists of partner Christina Kokko together with, among others, associates Maria Dahlin, Hayaat Ibrahim, Oscar Wennerström, Karolina Cohrs, Elias Lundin, Sophia Holm and Jasmin Draszka-Ali.
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026